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AUC

:   area under the plasma concentration curve

CyBorD

:   cyclophosphamide-bortezomib-dexamethasone

DCA

:   dichloroacetate

DEX

:   dexamethasone

DiCAM

:   DiChloroAcetate in Myeloma

IMWG

:   International Myeloma Working Group

LEN

:   lenalidomide

MM

:   multiple myeloma

PDH

:   pyruvate dehydrogenase

PDK

:   pyruvate dehydrogenase kinase

PN

:   peripheral neuropathy

SNP

:   single nucleotide polymorphism

TNSc

:   Total Neuropathy Score

1. INTRODUCTION {#prp2526-sec-0001}
===============

Deregulated energetics is an established hallmark of cancer that includes the glycolytic phenotype (elevated glucose uptake and glycolysis, with conversion of pyruvate to lactate in the presence of adequate oxygen).[1](#prp2526-bib-0001){ref-type="ref"}, [2](#prp2526-bib-0002){ref-type="ref"} The glycolytic phenotype is widespread amongst many cancer types, and is exploited clinically in imaging of cancers with \[^18^F\]‐fluorodeoxyglucose positron emission tomography (^18^F‐FDG PET).[2](#prp2526-bib-0002){ref-type="ref"}, [3](#prp2526-bib-0003){ref-type="ref"} Dichloroacetate (DCA) is an established investigational drug that can target the deregulated energetics of cancer. DCA reverses the glycolytic phenotype, redirecting the metabolism of pyruvate away from lactate production and into mitochondrial oxidation.[4](#prp2526-bib-0004){ref-type="ref"}, [5](#prp2526-bib-0005){ref-type="ref"} It does this through the inhibition of pyruvate dehydrogenase (PDH) kinases (PDKs) <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=608>, a family of four kinases (PDK1‐4) that phosphorylate and inactivate PDH.[5](#prp2526-bib-0005){ref-type="ref"} Antitumor activity in vivo was first demonstrated in lung and breast cancer models,[6](#prp2526-bib-0006){ref-type="ref"}, [7](#prp2526-bib-0007){ref-type="ref"} and has subsequently been shown in a range of solid tumor types (reviewed in [4](#prp2526-bib-0004){ref-type="ref"}). The actions of DCA include inhibiting proliferation, inducing apoptosis, enhancing apoptosis of other cytotoxic agents (particularly those that target mitochondrial metabolism [8](#prp2526-bib-0008){ref-type="ref"}, [9](#prp2526-bib-0009){ref-type="ref"}, [10](#prp2526-bib-0010){ref-type="ref"}, [11](#prp2526-bib-0011){ref-type="ref"}), and inhibiting angiogenesis, through mechanisms including decreasing the mitochondrial membrane potential, increasing p53 activity, decreasing hypoxia inducible factor‐1α expression, and decreased VEGF expression.[4](#prp2526-bib-0004){ref-type="ref"}

With decades of clinical use in adults and children with congenital lactic acidosis,[12](#prp2526-bib-0012){ref-type="ref"}, [13](#prp2526-bib-0013){ref-type="ref"} DCA has progressed rapidly into clinical trials against cancer, resulting in four published reports on phase I/II trials in solid tumors.[14](#prp2526-bib-0014){ref-type="ref"}, [15](#prp2526-bib-0015){ref-type="ref"}, [16](#prp2526-bib-0016){ref-type="ref"}, [17](#prp2526-bib-0017){ref-type="ref"} Chu et al[14](#prp2526-bib-0014){ref-type="ref"} concluded the recommended phase 2 dose (RP2D) for oral DCA is 6.25 mg/kg b.i.d., based on the maximum tolerated dose, with peripheral neuropathy (PN) arising after one or more months of treatment being one of the most common concerns, however, high variability in pharmacokinetics and the occurrence of neuropathy was observed among patients.[14](#prp2526-bib-0014){ref-type="ref"} The previous DCA trials in cancer included limited drug serum concentration monitoring, thus it remains unclear whether the RP2D is adequate for efficacy in the cancer setting. Further, it was noted in two of the trials[16](#prp2526-bib-0016){ref-type="ref"}, [17](#prp2526-bib-0017){ref-type="ref"} that it took several weeks for DCA to become detectable in serum, suggesting a loading dose may be of value. Thus, an effective dosing regimen of DCA for the treatment of cancer patients has not been established. An expected effective concentration of DCA can be proposed based on its ability to inhibit the PDKs in vitro. DCA is a pan‐PDK inhibitor, with the constitutive isoform, PDK2, having the lowest IC~50~ (0.2 mmol/L), whereas PDK1 and PDK3 require considerably more DCA for inhibition (1.0 mmol/L and 8.0 mmol/L, respectively).[5](#prp2526-bib-0005){ref-type="ref"}, [18](#prp2526-bib-0018){ref-type="ref"} PDK1 and PDK3 are both target genes of the transcription factor hypoxia inducible factor (HIF), and so may be expressed at elevated levels in hypoxic regions of solid cancers.[5](#prp2526-bib-0005){ref-type="ref"}

DCA is metabolized primarily in the liver by glutathione transferase Zeta (GSTZ1). The *GSTZ1* gene has three common nonsynonymous single nucleotide polymorphisms (SNPs) resulting in four common isoforms of the protein[19](#prp2526-bib-0019){ref-type="ref"}, [20](#prp2526-bib-0020){ref-type="ref"} and one rare isoform.[21](#prp2526-bib-0021){ref-type="ref"} The four main isoforms have been characterized in vitro for activity with haloacids, with GSTZ1\*A» GSTZ1\*B \~ GSTZ1\*C \> GSTZ1\*D for activity toward DCA.[19](#prp2526-bib-0019){ref-type="ref"}, [20](#prp2526-bib-0020){ref-type="ref"} *GSTZ1* also has polymorphisms in the promoter, including SNP rs7160195 at nt −1002, which impact on the level of expression of luciferase reporter constructs,[22](#prp2526-bib-0022){ref-type="ref"} and may alter the level of enzyme expression in the liver.[23](#prp2526-bib-0023){ref-type="ref"} A luciferase reporter promoter construct containing the −1002G vs −1002A allele resulted in approximately sixfold higher promoter activity when tested in transiently transfected HepG2 cells (figure 5B in[22](#prp2526-bib-0022){ref-type="ref"}). Consistent with this, expression of GSTZ1 in frozen human liver samples, estimated by both protein and mRNA‐based methods, was found to be approximately threefold higher in Caucasians who did not carry the −1002A allele (figures 1 and 3 in [23](#prp2526-bib-0023){ref-type="ref"}). It should be noted that these associations are not necessarily true in African‐Americans, where different haplotypes are present.[22](#prp2526-bib-0022){ref-type="ref"}, [23](#prp2526-bib-0023){ref-type="ref"} The impact of the genetic variants of *GSTZ1* on DCA kinetics and dynamics in patients has been reported in only a small number of individuals, and in only one of the cancer clinical trials,[15](#prp2526-bib-0015){ref-type="ref"} but has led to the development of a test to enable genetic‐based dosing for DCA.[24](#prp2526-bib-0024){ref-type="ref"}

In addition to genetic polymorphisms influencing DCA pharmacokinetics, DCA is an inhibitor of its own metabolism, irreversibly inhibiting GSTZ1 activity and leading to degradation of the protein,[25](#prp2526-bib-0025){ref-type="ref"}, [26](#prp2526-bib-0026){ref-type="ref"} explaining why subsequent doses of DCA have a longer half‐life compared to the initial dose.[27](#prp2526-bib-0027){ref-type="ref"} This adds complexity in understanding when DCA might achieve steady‐state concentrations during multiple dosing, requiring pharmacokinetic investigations on multiple days. Furthermore, giving a loading dose to achieve steady‐state concentrations more rapidly may be a useful strategy.

Multiple myeloma (MM) is a plasma cell malignancy affecting bone marrow and lytic lesions in the bones that remains incurable despite improvements in therapy including cyclophosphamide‐bortezomib‐dexamethasone (CyBorD or CVD), lenalidomide/ thalidomide, melphalan, and autologous stem cell transplantation.[28](#prp2526-bib-0028){ref-type="ref"}, [29](#prp2526-bib-0029){ref-type="ref"} Poor prognostic variants are often related to clonal genetic aberrations including 1p‐ and t(4,14) amongst others.[30](#prp2526-bib-0030){ref-type="ref"}, [31](#prp2526-bib-0031){ref-type="ref"} MM is associated with expression of a clonal immunoglobulin protein (paraprotein or M‐band) that is used routinely to monitor disease and assess response to therapy. The importance of metabolism changes has only recently been appreciated in hematological cancers.[32](#prp2526-bib-0032){ref-type="ref"} The metabolic phenotype of myeloma includes the glycolytic phenotype, present in approximately 50% of MM cell lines examined,[33](#prp2526-bib-0033){ref-type="ref"}, [34](#prp2526-bib-0034){ref-type="ref"} with high lactate dehydrogenase (LDH) and PDK1 expression associated with poorer patient outcomes[33](#prp2526-bib-0033){ref-type="ref"} and drug resistance, which may be overcome by reversing the glycolytic phenotype.[35](#prp2526-bib-0035){ref-type="ref"}, [36](#prp2526-bib-0036){ref-type="ref"} DCA combined with bortezomib showed additive cytotoxic effects in vitro and improved outcomes in a mouse model.[34](#prp2526-bib-0034){ref-type="ref"} Most recently, lactate has been identified as a survival factor,[37](#prp2526-bib-0037){ref-type="ref"} and inhibition of lactate transporters (MCTs) could reduce cell viability.[37](#prp2526-bib-0037){ref-type="ref"}, [38](#prp2526-bib-0038){ref-type="ref"} Extrapolating from these observations of the glycolytic phenotype, MM patients may be good candidates to benefit from DCA treatment.

In this study, we designed the DiCAM (DiChloroAcetate in Myeloma) clinical trial to improve upon previous trials. Pharmacogenetics were examined in both the acute and chronic treatment settings. The spectrum of cancer types treated with DCA was expanded into hematological malignancies, and MM patients were chosen allowing easy monitoring of disease via blood paraprotein levels. The MM patients were in plateau phase and in relatively good health, increasing the likelihood of them completing the treatment regimen and giving reliable pharmacokinetic information. Existing PN was not an exclusion criteria so that the significance of this potential side effect could be examined in a real patient setting. A loading dose of DCA was included to take advantage of the inhibition of GSTZ1, which was predicted to lead to more rapid achievement of therapeutic concentrations. While conducted in a limited number of patients, this study has been able to provide valuable insights for improved future trial design for testing efficacy of DCA in cancer patients.

2. MATERIALS AND METHODS {#prp2526-sec-0002}
========================

This study was approved by the ACT Health Human Research Ethics Committee and the Australian National University Human Research Ethics Committee. The study was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR registration number: ACTRN12615000226505).

2.1. Patient Eligibility {#prp2526-sec-0003}
------------------------

Patients were eligible for inclusion if they had: plasma cell myeloma in plateau phase (defined as neither progression nor response for at least 28 days); no change in myeloma therapy for at least 16 weeks (except bisphosphonates), excluding reinduction therapy, but enabling recruitment if stable on maintenance therapy; aged over 18 years; an Eastern Cooperative Oncology Group performance score of ≤2 and; a life expectancy of at least 6 months and; measurable disease (defined as quantifiable serum paraprotein on electrophoresis of at least 2 g/L, or elevated free kappa (\>21 mg/L) or lambda light chains (\>30 mg/L) with an abnormal serum free light chain ratio (normal κ:λ = 0.26‐1.26). Progression was defined as per International Myeloma Working Group (IMWG) to include an increase in the paraprotein by ≥25% and at least 5g/L, or \>25% increase in difference between involved and uninvolved light chain level, with an absolute increase of \>0.1g/L. Response was defined as at least an IMWG minimal response, including a reduction in the paraprotein by ≥25%.[39](#prp2526-bib-0039){ref-type="ref"} In the case of light chain only myeloma, a modified criteria of a 25% decrease in the difference between the involved and uninvolved light chains and an absolute reduction of at least 100 mg/L was chosen as a minimal response criteria is not available for light chain only myeloma.

2.2. Study Design {#prp2526-sec-0004}
-----------------

This was a prospective, open label, nonrandomized phase 2 study (Simon\'s Mini‐max 2‐stage design) of the efficacy of DCA in plateau phase myeloma. The recruitment aim was for 15 patients in the first stage, and 10 patients in the second stage. The primary efficacy endpoint was the overall response rate during 12 weeks of treatment. The secondary objectives were to (a) establish the drug concentrations of DCA in vivo with the dosing schedule, (b) confirm the tolerability and safety of DCA at these doses, and (c) genotype patients for glutathione transferase Zeta (*GSTZ1*) and correlate genotypes with DCA concentrations and tolerability.

The final patient in this cohort (P007) was enrolled in an updated protocol which is ongoing. The dosing on d1 in the new protocol is identical to the DiCAM protocol, thus the pharmacokinetic and pharmacogenetic results of P007 on d1 are reported in this study, as P007 shares an uncommon genotype with P001. The updated protocol deviates from this protocol after d3, thus no other results from P007 are consistent with the patient cohort and so are not reported here.

2.3. Drug formulation and dosing {#prp2526-sec-0005}
--------------------------------

Clinical grade crystalline sodium DCA (TCI America, Portland, OR) was purchased and compounded into 500 mg, 125 mg, and 25 mg gelatine capsules with inert filler by Capital Compounding Pharmacists (Woden, ACT, Australia). Capsules were prepared as patients were recruited, stored by The Canberra Hospital Oncology Pharmacy, and dispensed within 6 months of compounding. Patients received five doses of 25 mg/kg over days 1‐3: dose 1 in the morning of d1, then 25 mg/kg b.i.d. on d2 and 3. From d4 onwards, the dose was 6.25 mg/kg b.i.d., with the exception of d8, when a single dose of 25 mg/kg was given in the morning, to replicate the pharmacokinetic measurements of d1. DCA treatment was in addition to other maintenance treatments and was continued for 12 weeks, at which time DCA was discontinued.

2.4. Monitoring of patient residual disease and DCA toxicity {#prp2526-sec-0050}
------------------------------------------------------------

A physical examination including Total Neuropathy Score (TNSc),[40](#prp2526-bib-0040){ref-type="ref"} blood counts, serum biochemistry tests were undertaken at baseline and repeated on day 8, 28, 56, 84, 112 (4 months), 168 (6 months), and 252 (9 months) of the trial. Paraprotein level and/or free light chain levels were measured at baseline and days 28, 56, 84, 112, 168, and 252. Patients were withdrawn for new onset or progression to Grade‐3 peripheral neuropathy (defined as any of the seven aspects of TNSc having a score \> 3), or any other emergent grade 3 or 4 toxicity if the symptoms were not alleviated after supportive treatments.

2.5. Patient serum pharmacokinetic sampling {#prp2526-sec-0007}
-------------------------------------------

Measurements of serum DCA concentrations were made for determination of pharmacokinetics of DCA on d1 and d8 of the study. Blood samples were collected at time 0, 1, 2, 3, 4, 5, 6, and 24 hours after administration of DCA. For ongoing monitoring of DCA concentrations, the original protocol onto which P001 was recruited collected through samples only on d28, d56, and d84. This was revised for the subsequent patients to include collection of trough and peak concentrations as follows: On d15 and d22, blood samples were taken before DCA administration to measure maintenance dose trough concentration. On d28, d56, and d84, blood samples were taken before and 2 hours after DCA administration to monitor the maintenance dose trough concentration and peak concentration.

2.6. DNA isolation, genotyping, and haplotype analysis {#prp2526-sec-0008}
------------------------------------------------------

DNA was extracted from peripheral blood (QIAGEN blood kit, Cat.No.51106) and *GSTZ1* genotyping was performed by published methods for SNPs in the promoter (nt −1002, rs7160195) and in protein‐coding exons (nt 94, rs3177427; nt 124, rs7972; and nt 245, rs1046428). Haplotypes were inferred from those present in the Australian European population studied previously.[19](#prp2526-bib-0019){ref-type="ref"}, [20](#prp2526-bib-0020){ref-type="ref"} The expected proteins are described with the standard nomenclature for glutathione transferases.[41](#prp2526-bib-0041){ref-type="ref"}

2.7. Analysis of serum DCA concentrations {#prp2526-sec-0009}
-----------------------------------------

Serum DCA concentrations were analyzed in duplicate by liquid chromatography‐mass spectrometry (LC‐MS) for patients P001‐P004, and by gas chromatography‐mass spectrometry (GC‐MS) for patients P005‐P007. Prism 7 was used to calculate the area under the plasma concentration curve (AUC) on d1 from 0‐6 hours and the half‐life of DCA (using a nonlinear regression, one phase decay curve fit) from drug concentrations on d1 from peak (at 1 or 2 hours) to 6 hours (See Appendix [S1](#prp2526-sup-0001){ref-type="supplementary-material"} for details.)

2.8. In vitro drug combination studies {#prp2526-sec-0010}
--------------------------------------

The MM cell lines RPMI 8226, U266, NCI‐H929, MM.1S, and MM.1R were treated with DCA (D54702, Sigma Chemical Co St. Louis, MO) and chemotherapy agents for 72 or 96 hours, and the neutral red uptake assay was used to determine total viable cell number, expressed as a percentage of untreated/vehicle control cells. (See Appendix [S1](#prp2526-sup-0001){ref-type="supplementary-material"} for full details.) At least three independent experiments were performed for each treatment.

3. RESULTS {#prp2526-sec-0011}
==========

3.1. Patient characteristics {#prp2526-sec-0012}
----------------------------

Six Caucasian patients were enrolled in this study between May 2015 and June 2016. Patient demographics, baseline disease, prior treatments, and comorbidities are listed in Table [1](#prp2526-tbl-0001){ref-type="table"}. Four of these six patients had myeloma with intact paraproteins, whereas two patients had free light chain myeloma (P001, free kappa; P002 free lambda). The mean age at enrollment was 65.6 years (range 52‐77). They had 2‐7 prior therapies. Five of six patients were on comaintenance treatments during the study (Table [1](#prp2526-tbl-0001){ref-type="table"}). Maintenance treatment in P002 (CyBorD) was stopped at study d30 due to steroid myopathy and insomnia.

###### 

Patient characteristics

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient ID                                 P001                                           P002                         P003           P004                                             P005                       P006
  ------------------------------------------ ---------------------------------------------- ---------------------------- -------------- ------------------------------------------------ -------------------------- ------------------------
  Age of enrollment                          70                                             72                           77             61                                               62                         52

  Gender                                     Male                                           Male                         Female         Male                                             Male                       Male

  Age of diagnosis                           65                                             62                           75             60                                               60                         49

  Diagnosis (year)                           2010                                           2005                         2013           2014                                             2013                       2012

  Ethnicity                                  Caucasian                                      Caucasian                    Caucasian      Caucasian                                        Caucasian                  Caucasian

  Cytogenetics                               Normal                                         Unknown                      Normal         Complex [b](#prp2526-note-0005){ref-type="fn"}   Normal                     Normal

  Light chain only myeloma (κ/*λ*)           No                                             λ                            No             No                                               No                         No

  Intact paraprotein\                        [a](#prp2526-note-0004){ref-type="fn"} IgA/κ   No                           IgG/κ          IgG/ λ                                           IgG/ λ                     IgG/κ
  (HC/LC Isotypes)                                                                                                                                                                                                  

  Baseline disease                           FLC (λ‐κ)\                                     FLC (λ‐κ)\                   Paraprotein\   Paraprotein\                                     Paraprotein\               Paraprotein\
                                             45 mg/L                                        239 mg/L                     9 g/L          4 g/L                                            4 g/L                      10 g/L

  Comaintenance treatment                    None                                           CyBorD(until study day 30)   Thalidomide    Thalidomide, DEX                                 Thalidomide                Lenalidomide, DEX

  Best response received after 1st therapy   VGPR                                           VGPR                         SD             PR                                               PR                         PR

  Lines of prior therapy                     3                                              7                            2              3                                                3                          3

  Comorbidities                              Deep vein thrombosis/\                         Unknown                      Dyslipidemia   No                                               Gastro‐esophageal reflux   Deep vein thrombosis/\
                                             pulmonary embolism; kidney stones                                                                                                                                      pulmonary embolism
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CyBorD, Cyclophosphamide + Bortezomib +Dexamethasone; DEX: dexamethasone; CR, complete response; FLC, free light chain; HC, heavy chain; LC, light chain; sCR, stringent complete response; PR, partial response; SD, stable disease; VGPR, very good partial response.

P001: P001 showed an IgA paraprotein at diagnosis in 2010, but the IgA paraprotein was not detected after 5 years on the screening day for the trial in 2015, thus his disease readout was presented as free light chain myeloma.

P004 cytogenetics results: (43,X, Y, add (1)(q21), add (2)(p23), add (2)(q33), add (4)(p15), der (8) t (8; 17)(p21; q11.2), del (11)(p12), add (12)(q13), −13, t (14; 22)(q32; q12), −16, −16, −17, −20, +mar1‐3\[12\]/sdl, del (6)(q25)\[5\]/46, XX \[36\].

John Wiley & Sons, Ltd

Four patients had normal cytogenetics and one patient was untested (Table [1](#prp2526-tbl-0001){ref-type="table"}). Patient P004 had confirmed complex cytogenetics including chromosome 1 abnormalities, 14q32 rearrangements and monosomy 13 which are associated with poor prognosis.[30](#prp2526-bib-0030){ref-type="ref"}, [31](#prp2526-bib-0031){ref-type="ref"} P004 was withdrawn from the study after 1 month due to rapid disease progression.

3.2. Patient response {#prp2526-sec-0013}
---------------------

One of the six patients (P002) showed a response to DCA treatment at d28 maintained to d84 (Figure [1](#prp2526-fig-0001){ref-type="fig"}A, Figure [S1](#prp2526-sup-0001){ref-type="supplementary-material"}). Two patients had transient falls in measurable disease at d28 (P001 and P003), but did not meet response criteria. After DCA treatment was completed, P002 steadily progressed. P004 was taken off the trial at d28 due to disease progression. P005 had a 25% (1g) increase in paraprotein on d56, which did not meet criteria for progression and returned to the baseline level (4 g/L) and remained at that level throughout the rest of the trial. P006 had a gradual increase in paraprotein during the trial, reaching the criteria for disease progression on d84, the last day of DCA treatment (Figure [1](#prp2526-fig-0001){ref-type="fig"}A, Figure [S1](#prp2526-sup-0001){ref-type="supplementary-material"}).

![(A) Patient disease outcomes. Paraprotein level or FLC levels were measured at screening, and then on 28, 56, 84, 112, 168, and 252 of study. Patient disease readout was normalized to the baseline disease level on screening day (100%). DCA treatment period is indicated by the green bar. Graphs of raw readouts for each patient are included in Figure [S1](#prp2526-sup-0001){ref-type="supplementary-material"}. (B) Patient Total Neuropathy Scores (TNSc). The neuropathy of each patient was assessed through seven components, as described in the methods. Graphs detailing the seven component scores for each patient are included in Figure S2. DCA treatment period is indicated by the green bar](PRP2-7-e00526-g001){#prp2526-fig-0001}

3.3. Toxicity {#prp2526-sec-0014}
-------------

No patient withdrew from the trial due to DCA induced toxicity, and none required dose reduction during the 3‐month DCA treatment period. Blood counts, liver, and kidney function were not adversely affected, consistent with previous findings from DCA trials in cancer patients.[14](#prp2526-bib-0014){ref-type="ref"}, [15](#prp2526-bib-0015){ref-type="ref"}, [17](#prp2526-bib-0017){ref-type="ref"} There were no problems with compliance as indicated by interviewing the patients and return of unused medication.

Five of six patients started the trial with some PN from previous myeloma treatments, and five of six patients experienced some small increase in TNSc while on DCA, but the TNSc decreased after completing DCA treatment, indicating the PN induced by DCA was reversible (Figure [1](#prp2526-fig-0001){ref-type="fig"}B). On the last day of treatment (d84), P002 presented with a significant increase in TNSc, with both the strength and motor symptoms having a score of 3 (Figure [S2](#prp2526-sup-0001){ref-type="supplementary-material"}). This made his TNSc much higher than the other patients (Figure [1](#prp2526-fig-0001){ref-type="fig"}B), but as with the milder changes in the other patients, the symptoms gradually abated over the 6 months of monitoring after the DCA treatment was completed.

3.4. Pharmacokinetics {#prp2526-sec-0015}
---------------------

Serum DCA concentrations were determined on d1 and d8 of the trial after a single oral dose of 25 mg/kg taken at approximately 9 [am]{.smallcaps}. Patients were not given special breakfast instructions, which may contribute to variation in absorption rates and peak concentrations. The effect of food on DCA absorption has not been studied; published pharmacokinetic studies have always been done in initially fasting subjects. On d1, serum DCA concentrations peaked rapidly in all patients (median peak time 1 hour, mean peak concentration 0.33 mmol/L, range 0.15‐0.68 mmol/L, Figure [2](#prp2526-fig-0002){ref-type="fig"}A). DCA was then cleared with a mean half‐life of 93 min (Table [2](#prp2526-tbl-0002){ref-type="table"}), with 90% of the drug being cleared by 6 hours, and DCA being undetectable at 24 hours (Figure [2](#prp2526-fig-0002){ref-type="fig"}A). Notably, P001 and P007 had faster apparent clearance of DCA compared to other patients (CL/F \> 65 L/h, Table [2](#prp2526-tbl-0002){ref-type="table"}). This was also reflected in a smaller AUC (Table [2](#prp2526-tbl-0002){ref-type="table"}) and a sharp drop in DCA concentrations between 1 and 2 hours (Figure [2](#prp2526-fig-0002){ref-type="fig"}A). On d8 of the study (Figure [2](#prp2526-fig-0002){ref-type="fig"}B), the same oral dose of 25 mg/kg DCA resulted in peak serum concentrations approximately twofold those achieved on d1 (median peak time 2 hours, mean peak concentration 0.59 mmol/L, range 0.50‐0.66 mmol/L on d8). The serum DCA concentration remained high (0.3‐0.6 mmol/L) 6 hours post‐DCA administration, and was readily detected at 24 hours. In contrast to d1, on d8 the drug concentration profile of P001 was not remarkably different from other patients. (P007 d8 could not be compared due to a different dosing regime in the modified protocol.)

![Patient serum DCA pharmacokinetics on (A) day 1, and (B) day 8 of the trial. Serum was collected hourly after a single oral dose of 25 mg/kg (high loading dose), and DCA measured by mass spectrometry](PRP2-7-e00526-g002){#prp2526-fig-0002}

###### 

Patient *GSTZ1* genotypes and correlation with DCA metabolism

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                        [a](#prp2526-note-0006){ref-type="fn"}Half‐life DCA (min)\   [a](#prp2526-note-0006){ref-type="fn"}AUC\   [b](#prp2526-note-0007){ref-type="fn"}CL/F\   Haplotypes/\            [c](#prp2526-note-0008){ref-type="fn"}Average trough \[DCA\]\   Promoter\          
                        Day 1                                                        (mg/L.h)\                                    (L/h)\                                        Protein Isoforms        (mmol/L)                                                        nt −1002           
                                                                                     Day 1                                        Day 1                                                                                                                                                    
  --------------------- ------------------------------------------------------------ -------------------------------------------- --------------------------------------------- ----------------------- --------------------------------------------------------------- ------------------ ---------
  P001                  **61**                                                       **34.8**                                     **50.3**                                      ***Z1\*A*** */ Z1\*C*   (**KRT**/EGT)                                                   0.13 (n = 4)       A/G

  P002                  53                                                           92.8                                         21.5                                          *Z1\*B/ Z1\*B*          (KGT/KGT)                                                       **0.34 (n = 5)**   **A/A**

  P003                  125                                                          107.7                                        13.9                                          *Z1\*C/ Z1\*D*          (EGT/EGM)                                                       0.10 (n = 5)       G/G

  P004                  79                                                           89.7                                         23.7                                          *Z1\*C/ Z1\*C*          (EGT/EGT)                                                       0.04 (n = 4)       G/G

  P005                  105                                                          217.4                                        12.6                                          *Z1\*C/ Z1\*D*          (EGT/EGM)                                                       0.21 (n = 5)       G/G

  P006                  201                                                          140.2                                        16.1                                          *Z1\*C/ Z1\*C*          (EGT/EGT)                                                       0.17 (n = 6)       G/G

  P007                  **25**                                                       **47.4**                                     **34.2**                                      ***Z1\*A*** */ Z1\*C*   (**KRT**/EGT)                                                   N/A                A/G

  *Means by Genotype*                                                                                                                                                                                                                                                                      

  Protein --\           93                                                           104.3                                        24.6                                                                                                                                                      
  All genotypes                                                                                                                                                                                                                                                                            

  P002‐P006\            113                                                          129.6                                        17.6                                                                                                                                                      
  (No Z1\*A)                                                                                                                                                                                                                                                                               

  P001, P007\           43                                                           41.1                                         42.3                                                                                                                                                      
  (One Z1\*A)                                                                                                                                                                                                                                                                              

  Promoter nt −1002\                                                                                                                                                                                                                                                    0.165               
  All genotypes                                                                                                                                                                                                                                                                            

  G/G and G/A (n = 5)                                                                                                                                                                                                                                                   0.130               

  A/A (P002)                                                                                                                                                                                                                                                            0.34                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After the initial dose of 25 mg/kg.

Apparent clearance (CL/F).

During the 3 month maintenance treatment period (6.25 mg/kg b.i.d.). Average derived from values presented in Table [S1](#prp2526-sup-0001){ref-type="supplementary-material"}

Bold indicates the unusual values and genotypes discussed in the text.

John Wiley & Sons, Ltd

The serum trough and peak (2 hours post dose) concentrations were monitored during the 3 month DCA maintenance treatment (6.25 mg/kg b.i.d.). The average DCA trough concentration increased with time, from 0.074 mmol/L on d8 to 0.309 mmol/L on d84 (Figure [3](#prp2526-fig-0003){ref-type="fig"}A, Table [S1](#prp2526-sup-0001){ref-type="supplementary-material"}). This trough concentration range is very similar to the data reported by Chu et al.[14](#prp2526-bib-0014){ref-type="ref"} Strikingly, P002 had DCA trough concentrations two‐ to threefold higher than the average of the other patients on d56 and d84 (Figure [3](#prp2526-fig-0003){ref-type="fig"}A, Table [S2](#prp2526-sup-0001){ref-type="supplementary-material"}), correlating with the highest TNSc (Figure [1](#prp2526-fig-0001){ref-type="fig"}B). Neither neuropathy score nor trough concentrations were elevated during the first month of DCA treatment. The DCA peak concentrations ranged from 0.04 to 0.69 mmol/L when patients were on maintenance dose (Figure [3](#prp2526-fig-0003){ref-type="fig"}B, Table [S1](#prp2526-sup-0001){ref-type="supplementary-material"}).

![Patient serum DCA (A) trough and (B) peak concentrations over 12 weeks of the trial. Serum was collected before (trough) and 2 h after (peak) the morning oral maintenance dose of 6.25 mg/kg. Full details of values and variations in data points collected for each patient are included in Table [S1](#prp2526-sup-0001){ref-type="supplementary-material"}. (Note: Peak concentration samples were not collected under the original protocol onto which P001 was recruited.)](PRP2-7-e00526-g003){#prp2526-fig-0003}

3.5. Pharmacogenetics {#prp2526-sec-0016}
---------------------

We determined the genotypes of the patients for the common promoter and coding region SNPs of *GSTZ1*. Overall, the alleles present in our seven patients were consistent with expected frequencies for Caucasians. Notably, P001 and P007 possessed one allele of *GSTZ1\*A*, a minor haplotype with 3.6‐fold enzymatic activity toward DCA in vitro compared to wild‐type protein.[20](#prp2526-bib-0020){ref-type="ref"} The presence of *GSTZ1\*A* correlated with the shorter half‐life of DCA and lower AUC on d1 (Figure [2](#prp2526-fig-0002){ref-type="fig"}A, Table [2](#prp2526-tbl-0002){ref-type="table"}).

All isoforms of GSTZ1 are irreversibly inactivated by DCA requiring expression of new protein to restore enzyme activity. Promoter SNPs have been described that result in expression differences of GSTZ1. An A at nt −1002 is associated with lower promoter activity in vitro[22](#prp2526-bib-0022){ref-type="ref"} and lower protein expression in human liver.[23](#prp2526-bib-0023){ref-type="ref"} P002 possessed an uncommon genotype at nt −1002, being homozygous A for the low activity promoter. This correlated with the highest average DCA trough concentration (Figure [3](#prp2526-fig-0003){ref-type="fig"}, Table [2](#prp2526-tbl-0002){ref-type="table"}) and the highest TNSc (Figure [1](#prp2526-fig-0001){ref-type="fig"}B).

3.6. Drug combinations in vitro {#prp2526-sec-0017}
-------------------------------

We examined the effect of DCA in combination with CyBorD on cell viability of myeloma cell lines in vitro. A fixed ratio of the cytotoxic agents (400: 1: 10, based on P002's CyBorD dosing regimen) for cyclophosphamide: bortezomib: dexamethasone (DEX) was tested against U266 and RPMI 8226 cells, which have previously been shown to have different levels of glycolytic activity.[34](#prp2526-bib-0034){ref-type="ref"} Consistent with Sanchez et al,[34](#prp2526-bib-0034){ref-type="ref"} 5 mmol/L DCA alone significantly reduced the total viable cell number of RPMI 8226 cells (high glycolytic activity), but not U266 cells (low glycolytic activity) (Figure [4](#prp2526-fig-0004){ref-type="fig"}A). Regardless of this difference in response to DCA alone, DCA did not increase the effectiveness of cytotoxic doses of the CyBorD drug combination in either cell line (Figure [4](#prp2526-fig-0004){ref-type="fig"}A).

![In vitro total viability cell number of cell lines treated with DCA in combination with myeloma maintenance therapies used during the trial. RPMI 8226 and U266 cell lines were treated with 5 mmol/L DCA in combination with (A) CyBorD (72 h), (B) DEX (72 h), (C) LEN (96 h), or (D) LEN + DEX (96 h). CyBorD combination was at a fixed ratio of 400:1:10, where 1x concentrations were 4000 nmol/L cyclophosphamide, 10 nmol/L bortezomib, and 100 nmol/L dexamethasone. All data points shown represent mean ± SD from at least three independent experiments. \*\**P* \< .01 and \*\*\**P* \< .001 compared to non‐DCA‐treated counterpart. †*P* \< .001 for all points in the series. (Note: x‐axes are not linear/ logarithmic.)](PRP2-7-e00526-g004){#prp2526-fig-0004}

The impact of DCA on cell viability in vitro when used in combination with the standard myeloma therapies DEX and lenalidomide (LEN) was also examined. RPMI 8226 cells were moderately sensitive to DEX, whereas U266 cells were unresponsive (Figure [4](#prp2526-fig-0004){ref-type="fig"}B). The addition of DCA to low concentrations of DEX further decreased total viable cell number in RPMI8226 cells, however, the viability of U266 cells did not change. Neither cell line was sensitive to LEN at the concentrations tested (Figure [4](#prp2526-fig-0004){ref-type="fig"}C). DCA was effective at reducing total viable cell number in the presence of LEN in RPMI 8226 cells but did not alter total viable cell number of U266 cells treated with LEN (Figure [4](#prp2526-fig-0004){ref-type="fig"}C). Similarly, when DCA was added the combination of LEN and DEX, there was no difference in total viable cell number (Figure [4](#prp2526-fig-0004){ref-type="fig"}D). A similar lack of synergistic effect of DCA with these agents was observed in the additional myeloma cell lines MM.1S and MM.1R which were sensitive to LEN (Figure [S3](#prp2526-sup-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#prp2526-sec-0018}
=============

Targeting the cancer metabolic phenotype may offer a novel cancer treatment strategy not yet in routine clinical use. The glycolytic phenotype has received much interest, as it can be targeted by DCA, a prototypic pan‐PDK inhibitor that has been in clinical use for other indications for decades.[4](#prp2526-bib-0004){ref-type="ref"} In this small pilot study we found that, although response rates were low, there were very different pharmacokinetic profiles for DCA which are likely to have impacted both on the response rates and toxicity and suggest alternative approaches to dosing may be required.

Several early phase clinical trials in cancer have demonstrated its low toxicity and safety in patients with solid tumors, with reversible PN being the primary concern.[14](#prp2526-bib-0014){ref-type="ref"}, [15](#prp2526-bib-0015){ref-type="ref"}, [16](#prp2526-bib-0016){ref-type="ref"}, [17](#prp2526-bib-0017){ref-type="ref"} In this study, we too found that PN was the only significant side effect, seen only after chronic use and was reversible. Five of six patients entered the trial with some preexisting PN, which was not greatly exacerbated by DCA at 6.25 mg/kg b.i.d., thus DCA can be used in patients with existing peripheral neuropathy.

Significant DCA‐related PN was only experienced in one patient, P002 (Figure [1](#prp2526-fig-0001){ref-type="fig"}B) in association with higher trough DCA concentrations (Figure [3](#prp2526-fig-0003){ref-type="fig"}A) and an uncommon *GSTZ1* genotype -- homozygosity for the −1002A promoter SNP (Table [2](#prp2526-tbl-0002){ref-type="table"}). The −1002A promoter allele has been demonstrated to have reduced activity in vitro.[22](#prp2526-bib-0022){ref-type="ref"} We propose that during chronic DCA treatment, when GSTZ1 is persistently inactivated and degraded, −1002A/A individuals will re‐express GSTZ1 protein at a lower rate or level making them more susceptible to chronic accumulation of DCA and thus PN. This reduced ability to re‐express the protein may be more important in determining DCA kinetics and side effects than the activity (ie, protein haplotype) of the enzyme toward DCA.

In Caucasians, −1002A is in dis‐equilibrium with E32K[23](#prp2526-bib-0023){ref-type="ref"} (ie, GSTZ1\*A (KRT) or GSTZ1\*B (KGT)). These two isoforms are \~3.6‐fold different in activity toward DCA[20](#prp2526-bib-0020){ref-type="ref"} and thus this weaker promoter may express protein with high (GSTZ1\*A) or intermediate (GSTZ1\*B) catalytic activity. P002 was homozygous Z1\*B, which would be predicted to be the most susceptible/ lowest activity combination genotype. Heterozygosity for −1002A in P001 did not associate with unusual peak or trough DCA concentrations, suggesting that homozygosity is necessary for the phenotype to be significant. The −1002A SNP has a population frequency of 0.33 in Australian Europeans,[22](#prp2526-bib-0022){ref-type="ref"} which would result in homozygotes constituting 11% of the population.

In addition to having the highest total neuropathy score, P002 also demonstrated the strongest reduction in disease in response to DCA treatment, maintaining a response until the end of the treatment period (Figure [1](#prp2526-fig-0001){ref-type="fig"}A). This may be attributed to the high drug concentrations experienced by P002 compared to the other patients. The alternative explanation of a combination effect of DCA with CyBortD was explored in vitro, but no synergism was demonstrated. Thus, both the response and increased toxicity are attributable to altered drug concentrations due to underlying genetic polymorphisms.

The pharmacokinetics on d1 after the initial high dose of DCA (acute treatment setting) showed an interesting correlation between the GSTZ1\*A isoform and a reduced half‐life/ smaller AUC (Table [2](#prp2526-tbl-0002){ref-type="table"}) for DCA. However, this phenotype may be of less importance in the setting of long term cancer treatment, as the difference between P001 and other patients with different GSTZ1 genotypes had disappeared after 1 week of treatment (Figure [2](#prp2526-fig-0002){ref-type="fig"}B), presumably due to inactivation of GSTZ1 protein by DCA.

Considering the low frequency of homozygosity for the −1002A, the lack of difference between protein‐coding variants after 1 week of treatment, and that the DCA‐related PN only arose with chronic treatment and was reversible, it remains unclear that genotyping for *GSTZ1* before treatment is necessary for safe use of DCA. Should a −1002A/A genotype be detected, additional monitoring for PN and potential dose reduction could be implemented. None‐the‐less, a clinical genotyping assay for the protein‐coding *GSTZ1* variants has been developed.[24](#prp2526-bib-0024){ref-type="ref"} Note that this test does not consider the promoter SNPs, and so may be overlooking an important component of DCA pharmacogenetics. For the genotyping test to be most informative for predicting a personalized dose, both the promoter and coding SNPs need to be considered. Analysis of additional patients for both DCA pharmacokinetics and pharmacogenetics is warranted to be sure of the impact of *GSTZ1* genotypes on DCA concentrations.

Previous trials of DCA in brain and solid cancers showed that DCA therapy was associated with disease stabilization in heavily pretreated patients.[14](#prp2526-bib-0014){ref-type="ref"}, [15](#prp2526-bib-0015){ref-type="ref"} Similarly, our evidence of response is modest, with only one patient (P002) showing a response (Figure [1](#prp2526-fig-0001){ref-type="fig"}A). The initial low disease burden in these patients (Table [1](#prp2526-tbl-0001){ref-type="table"}) made robust detection of improvement difficult. The responder had the highest sustained DCA concentrations, but two others had minor reductions in the myeloma‐related proteins at d28, suggesting a trend toward a clinical response in 50% of patients, consistent with expected response rates from in vitro cell line data. We suggest this transient response may be due to the initial high loading dose of DCA, and that the average drug concentration range when on 6.25 mg/kg b.i.d. was not high enough to be effective. Excluding P002, trough concentrations ranged from 0.03 to 0.24 mmol/L, sufficient to inhibit PDK2 (IC~50~ 0.2 mmol/L), whereas peak concentrations ranged from 0.15 to 0.48 mmol/L. While this peak concentration may inhibit both PDK2 and PDK4 (IC~50~ 0.5 mmol/L), it remains below the IC~50~ for PDK1 (1.0 mmol/L) and PDK3 (8 mmol/L), which are likely to be induced in many cancer types.[5](#prp2526-bib-0005){ref-type="ref"} For this reason, patient recruitment to this version of the trial protocol was stopped, and our investigations are continuing with a modified dosing regimen that aims to maintain higher concentrations of DCA as observed on d8, while avoiding the chronic side effects of DCA treatment.

These discussions are based on DCA as a single agent, however, DCA is most likely to be used in combination regimens. In our in vitro studies, we saw no indication of beneficial combination interactions between DCA and commonly used myeloma treatments (Figure [4](#prp2526-fig-0004){ref-type="fig"} and Figure [S3](#prp2526-sup-0001){ref-type="supplementary-material"}), however, DCA did not interfere with their efficacy. Where DCA was effective alone, this effect was often additive with the other agents, particularly at low doses of the other agent. We cannot exclude the possibility of pharmacokinetic interactions between DCA and these drugs, as there are no published studies on this topic. However, based on our in vitro results, DCA may be most beneficial for myeloma patients where the cytotoxicity of the other drug is low (eg, Figure [4](#prp2526-fig-0004){ref-type="fig"}C) or when the concentration of the cytotoxic agent is low between doses (eg, Figure [4](#prp2526-fig-0004){ref-type="fig"}A and B).

This study concludes that further study of DCA in myeloma is warranted in patients with a higher disease burden and in combination with other therapies. While the small number of patients does not allow firm conclusions to be drawn about associations between *GSTZ1* genetics and pharmacokinetics or peripheral neuropathy, future studies should include *GSTZ1* genotyping of promoter and protein‐coding polymorphisms to address these questions in additional patients. Regardless of *GSTZ1* genotypes, a dosing regime based on drug concentrations and biomarkers rather than maximum tolerated dose, that can achieve higher concentrations without peripheral neuropathy is likely to be needed to achieve maximum benefit from DCA in the treatment of cancer.
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